A SNAPSHOT
OF A YEAR
OF PROGRESS
allowing patients with Lynch
syndrome like Adrienne Skinner
to live with no evidence
of disease, p. 78.
benefiting patients with
Merkel cell carcinoma,
like Carrie Best, p. 86.
effectively treating patients with head
and neck cancer, like Bill McCone, p. 82.
a PARP inhibitor for treating patients with ovarian
cancer, like Teri Woodhull, p. 70.
a PDGFR-alpha–targeted
therapeutic, which is
benefiting patients
with soft tissue sarcoma,
like Evan Freiberg, p. 66.
the first FLT3 inhibitor, which is benefiting
patients with acute myeloid leukemia, p. 61.
Research Continues
to Advance
Immunotherapy:
Research Continues
to Power
Precision Medicine:
9
new anticancer therapeutics.
8
previously approved anticancer
therapeutics for treating
new types of cancer.
1 new optical imaging agent.
Between August 1, 2016,
and July 31, 2017,
the FDA Approved:
Leading to new and expanded uses for
immunotherapeutics. These new treatments are:
Leading to new therapeutics that target specific
molecules involved in the cancer process, including:
